Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

N-acetylcysteine for Prevention of Contrast-Induced Nephropathy: A Narrative Review

  • Jo, Sang-Ho (Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital)
  • Published : 2011.12.30
⟨ Previous Next ⟩

Abstract

Contrast-induced nephropathy (CIN) affects in-hospital, short- and long-term morbidity and mortality. It also leads to prolonged hospital stay and increased medical cost. Given the potential clinical severity of CIN, there has been considerable interest in the development of preventative strategies to reduce the risk of contrast-induced renal deterioration in at-risk popul-ations. A number of pharmacologic and mechanical preventive measures have been attempted, but no method other than adequate periprocedural hydration has been conclusively successful. Since its introduction in 2000, N-acetylcysteine (NAC) has been widely investigated, albeit with conflicting findings for its nephroprotection capability in patients receiving contrast media procedures. However, there is still virtually no definitive evidence of effectiveness of NAC. Although the exact mechanism responsible for the protective action of NAC from renal function deterioration remains unclear, the antioxidant and vas-odilatory properties of NAC have been suggested as the main mechanisms. This review summarizes the current status of NAC as a potential agent to prevent renal functional deterioration and its limitations.

Keywords

References

  1. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
  2. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-6. https://doi.org/10.1053/ajkd.2002.32766
  3. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75. https://doi.org/10.1016/S0002-9343(97)00150-2
  4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998;32(5 Suppl 3):S112-9. https://doi.org/10.1053/ajkd.1998.v32.pm9820470
  5. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64. https://doi.org/10.1161/01.CIR.0000016043.87291.33
  6. Manske CL, Sprafka JM, Strony JT, Wang Y. Contrast nephropathy in azotemic diabetic patients undergoing coronary angiography. Am J Med 1990;89:615-20. https://doi.org/10.1016/0002-9343(90)90180-L
  7. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial: the Iohexol Cooperative Study. Kidney Int 1995;47:254-61. https://doi.org/10.1038/ki.1995.32
  8. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER Study: a randomized controlled trial. J Am Coll Cardiol 2006;48:924-30. https://doi.org/10.1016/j.jacc.2006.06.047
  9. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006;48:692-9. https://doi.org/10.1016/j.jacc.2006.02.073
  10. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004;291:2328-34. https://doi.org/10.1001/jama.291.19.2328
  11. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002;162:329-36. https://doi.org/10.1001/archinte.162.3.329
  12. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study: Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. J Am Coll Cardiol 1999;33:403-11. https://doi.org/10.1016/S0735-1097(98)00574-9
  13. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20. https://doi.org/10.1056/NEJM199411243312104
  14. Weinstein JM, Heyman S, Brezis M. Potential deleterious effect of furosemide in radiocontrast nephropathy. Nephron 1992;62:413-5. https://doi.org/10.1159/000187090
  15. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 1999;34:1682-8. https://doi.org/10.1016/S0735-1097(99)00422-2
  16. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003;290:2284-91. https://doi.org/10.1001/jama.290.17.2284
  17. Russo D, Testa A, Della Volpe L, Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel blocker. Nephron 1990;55:254-7. https://doi.org/10.1159/000185971
  18. Huber W, Schipek C, Ilgmann K, et al. Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol 2003;91:1157-62. https://doi.org/10.1016/S0002-9149(03)00259-5
  19. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75. https://doi.org/10.1016/S0002-9343(97)00150-2
  20. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4. https://doi.org/10.1056/NEJM200007203430304
  21. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 2004;25:206-11. https://doi.org/10.1016/j.ehj.2003.11.016
  22. Cotgreave I, Moldeus P, Schuppe I. The metabolism of N-acetylcysteine by human endothelial cells. Biochem Pharmacol 1991;42:13-6. https://doi.org/10.1016/0006-2952(91)90674-T
  23. Birck R, Krzossok S, Markowetz F, Schnulle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003;362:598-603. https://doi.org/10.1016/S0140-6736(03)14189-X
  24. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-94. https://doi.org/10.7326/0003-4819-148-4-200802190-00007
  25. Liu R, Nair D, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. J Gen Intern Med 2005;20:193-200. https://doi.org/10.1111/j.1525-1497.2005.30323.x
  26. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 2004;65:1366-74. https://doi.org/10.1111/j.1523-1755.2004.00516.x
  27. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? a meta-analysis. Am J Med 2004;117:938-47. https://doi.org/10.1016/j.amjmed.2004.06.046
  28. Trivedi H, Daram S, Szabo A, Bartorelli AL, Marenzi G. High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. Am J Med 2009;122:874.e9-15. https://doi.org/10.1016/j.amjmed.2009.01.035
  29. Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007;5:32. https://doi.org/10.1186/1741-7015-5-32
  30. Tepel M, Aspelin P, Lameire N. Contrast-induced nephropathy: a clinical and evidence-based approach. Circulation 2006;113:1799-806. https://doi.org/10.1161/CIRCULATIONAHA.105.595090
  31. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004;15:761-9. https://doi.org/10.1097/01.ASN.0000116241.47678.49
  32. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetyl-cysteine, and saline for prevention of radiocontrast-induced nephropathy: a comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures: a single-center prospective controlled trial. Am Heart J 2007;154:539-44. https://doi.org/10.1016/j.ahj.2007.05.012
  33. Barrett BJ, Parfrey PS. Prevention of nephrotoxicity induced by radiocontrast agents. N Engl J Med 1994;331:1449-50. https://doi.org/10.1056/NEJM199411243312111
  34. Pannu N, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006;295:2765-79. https://doi.org/10.1001/jama.295.23.2765
  35. Barrett BJ. Contrast nephrotoxicity. J Am Soc Nephrol 1994;5:125-37.
  36. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997;29:465-77. https://doi.org/10.1016/S0272-6386(97)90212-2
  37. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990;258(1 Pt 2):F115-20. https://doi.org/10.1152/ajpcell.1990.258.1.C115
  38. Messana JM, Cieslinski DA, Humes HD. Comparison of toxicity of radiocontrast agents to renal tubule cells in vitro. Ren Fail 1990;12:75-82. https://doi.org/10.3109/08860229009087121
  39. Katholi RE, Woods WT Jr, Taylor GJ, et al. Oxygen free radicals and contrast nephropathy. Am J Kidney Dis 1998;32:64-71. https://doi.org/10.1053/ajkd.1998.v32.pm9669426
  40. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992;41:1008-15. https://doi.org/10.1038/ki.1992.153
  41. DiMari J, Megyesi J, Udvarhelyi N, Price P, Davis R, Safirstein R. N-acetyl cysteine ameliorates ischemic renal failure. Am J Physiol 1997;272(3 Pt 2):F292-8.
  42. Salom MG, Ramirez P, Carbonell LF, et al. Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 1998;65:1315-21. https://doi.org/10.1097/00007890-199805270-00006
  43. Arstall MA, Yang J, Stafford I, Betts WH, Horowitz JD. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction: safety and biochemical effects. Circulation 1995;92:2855-62. https://doi.org/10.1161/01.CIR.92.10.2855
  44. Pollman MJ, Hall JL, Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury: influence of redox state and cell phenotype. Circ Res 1999;84:113-21. https://doi.org/10.1161/01.RES.84.1.113
  45. Romano G, Briguori C, Quintavalle C, et al. Contrast agents and renal cell apoptosis. Eur Heart J 2008;29:2569-76. https://doi.org/10.1093/eurheartj/ehn197
  46. Lee HC, Sheu SH, Liu IH, et al. Impact of short-duration administration of N-acetylcysteine, probucol and ascorbic acid on contrast-induced cytotoxicity. J Nephrol 2011 Apr 20 [Epub]. http://dx.doi.org/10.5301/JN.2011.7741.
  47. Jo SH, Koo BK, Park JS, et al. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. Am Heart J 2009;157:576-83. https://doi.org/10.1016/j.ahj.2008.11.010
  48. Briguori C, Airoldi F, D'Andrea D, et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007;115:1211-7.
  49. Solomon R. Contrast-medium-induced acute renal failure. Kidney Int 1998;53:230-42. https://doi.org/10.1038/sj.ki.4495510
  50. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:685-91. https://doi.org/10.1097/00004424-199911000-00004
  51. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992;41:1008-15. https://doi.org/10.1038/ki.1992.153
  52. Zhang H, Spapen H, Nguyen DN, Rogiers P, Bakker J, Vincent JL. Effects of N-acetyl-L-cysteine on regional blood flow during endotoxic shock. Eur Surg Res 1995;27:292-300.
  53. Salom MG, Ramirez P, Carbonell LF, et al. Protective effect of N-acetyl-L-cysteine on the renal failure induced by inferior vena cava occlusion. Transplantation 1998;65:1315-21. https://doi.org/10.1097/00007890-199805270-00006
  54. Mehta A, Sekhon CP, Giri S, Orak JK, Singh AK. Attenuation of ischemia/reperfusion induced MAP kinases by N-acetyl cysteine, sodium nitroprusside and phosphoramidon. Mol Cell Biochem 2002;240:19-29. https://doi.org/10.1023/A:1020675721351
  55. Khachigian LM, Collins T, Fries JW. N-acetyl cysteine blocks mesangial VCAM-1 and NF-kappa B expression in vivo. Am J Pathol 1997;151:1225-9.
  56. Brady HR, Singer GG. Acute renal failure. Lancet 1995;346:1533-40. https://doi.org/10.1016/S0140-6736(95)92057-9
  57. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet 1995;346:547-52. https://doi.org/10.1016/S0140-6736(95)91385-8
  58. Holt S, Goodier D, Marley R, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294-5. https://doi.org/10.1016/S0140-6736(05)74933-3
  59. Izzedine H, Kheder-Elfekih R, Deray G, Thabut D. Endothelin-receptor antagonist/N-acetylcysteine combination in type 1 hepatorenal syndrome. J Hepatol 2009;50:1055-6. https://doi.org/10.1016/j.jhep.2009.02.002
  60. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008;148:284-94. https://doi.org/10.7326/0003-4819-148-4-200802190-00007
  61. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769-75. https://doi.org/10.1161/01.CIR.0000103623.63687.21
  62. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 2006;354:2773-82. https://doi.org/10.1056/NEJMoa054209
  63. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: the LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol 2010;55:2201-9. https://doi.org/10.1016/j.jacc.2009.08.091
  64. Jaffery Z, Verma A, White CJ, et al. A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. Catheter Cardiovasc Interv 2011 May 3 [Epub]. http://dx.doi.org/10.1002/ccd.23157.
  65. Tanaka A, Suzuki Y, Suzuki N, et al. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? Intern Med 2011;50:673-7. https://doi.org/10.2169/internalmedicine.50.4226
  66. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004;15:407-10. https://doi.org/10.1097/01.ASN.0000106780.14856.55
  67. Poletti PA, Saudan P, Platon A, et al. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity. AJR Am J Roentgenol 2007;189:687-92. https://doi.org/10.2214/AJR.07.2356
  68. Ristikankare A, Kuitunen T, Kuitunen A, et al. Lack of renoprotective effect of i.v. N-acetylcysteine in patients with chronic renal failure undergoing cardiac surgery. Br J Anaesth 2006;97:611-6. https://doi.org/10.1093/bja/ael224
  69. Haase M, Haase-Fielitz A, Ratnaike S, et al. N-Acetylcysteine does not artifactually lower plasma creatinine concentration. Nephrol Dial Transplant 2008;23:1581-7. https://doi.org/10.1093/ndt/gfm818
  70. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-induced Nephropathy Trial (ACT). Circulation 2011;124:1250-9. https://doi.org/10.1161/CIRCULATIONAHA.111.038943
  71. McCullough PA, Khambatta S, Jazrawi A. Minimizing the renal toxicity of iodinated contrast. Circulation 2011;124:1210-1. https://doi.org/10.1161/CIRCULATIONAHA.111.054502
  72. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010;31:2501-55. https://doi.org/10.1093/eurheartj/ehq277
  73. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty 1. N Engl J Med 2006;354:2773-82. https://doi.org/10.1056/NEJMoa054209
  74. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med 2006;354:379-86. https://doi.org/10.1056/NEJMcp050801

Cited by

  1. Serum Neutrophil Gelatinase-Associated Lipocalin and Cystatin C are early Biomarkers of Contrast-Induced Nephropathy After Coronary Angiography in Patients With Chronic Kidney Disease vol.65, pp.5, 2011, https://doi.org/10.1177/0003319713483918
  2. High-dose atorvastatin for preventing contrast-induced nephropathy in primary percutaneous coronary intervention : vol.16, pp.3, 2011, https://doi.org/10.2459/jcm.0000000000000157
  3. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis. vol.37, pp.10, 2011, https://doi.org/10.3109/0886022x.2015.1012985
  4. Iso-osmolar Iodixanol Is Better than Low-osmolar Contrast for CIN Prevention. And Then? vol.51, pp.None, 2011, https://doi.org/10.4070/kcj.2020.0003